Health System SP Accelerators: Shields vs Clearway Health vs CarePathRx vs CPS Solutions

Thesis

The defining buyer question is no longer which accelerator has the nicest specialty-pharmacy story. It is which structural trade-off the health system is willing to accept:

• Shields remains the scale and contracting leader, but no longer offers a clean independence narrative after Evernorth’s 2025 preferred-equity financing.
• Clearway Health is the only scaled accelerator still positioned as payer-independent, but it comes with a smaller public footprint and fewer disclosed proof points.
• CarePathRx offers the broadest bundled health-system pharmacy stack, but buyers are now partnering directly with Evernorth.
• CPS Solutions is the broadest hospital-pharmacy operator overall, but specialty acceleration now sits inside Optum/UHG via Trellis Rx.

The companion analysis Health System Specialty Pharmacy: Build vs. Buy vs. Partner covers the larger four-path decision tree including de novo solo build and full outsource. This page focuses only on the accelerator set.

Snapshot

Attribute	Shields Health Solutions	Clearway Health	CarePathRx	CPS Solutions
Best short label	Scale leader	Independence leader	Broadest bundled stack	Broadest hospital-pharmacy operator
Payer alignment	Sycamore-controlled with Evernorth preferred equity	Payer-independent	Evernorth-owned	Optum / UHG-owned
Core model	Health-system SP accelerator	Health-system SP build / operate partner	Health-system SP + home infusion + 340B + telepharmacy stack	Hospital pharmacy management + Trellis Rx specialty acceleration
Public scale signal	80+ health systems; 1,000+ hospitals/clinics	Smaller footprint; public scale details limited	40+ health systems; ~1,000 hospitals	800+ hospital clients across broader pharmacy operations
Technology story	TelemetryRx is the clearest moat	Charter platform; more limited public detail	Broad operational stack across multiple assets	Broad operations platform; less specialty-tech distinctiveness
Primary advantage	Payer contracts, LDD access, maturity	Governance and channel alignment	Stack breadth and health-system breadth	Enterprise breadth and operating footprint
Primary buyer risk	Evernorth entanglement despite “independence” story	Smaller scale and less disclosed contracting depth	Direct Evernorth channel conflict	Direct Optum/UHG channel conflict

Strategic Differences

1. Governance and Independence

This is the category’s most important differentiator now.

• Clearway Health is the cleanest answer for buyers that want a payer-independent accelerator partner.
• Shields is still more independent than the fully owned PBM options, but the Evernorth preferred-equity structure means independence is no longer a binary yes.
• CarePathRx now sits directly inside Evernorth, which can simplify payer leverage for some systems but raises obvious channel-conflict questions.
• CPS Solutions sits inside Optum/UHG, creating the same structural question from the Optum side.

For many 2026 RFPs, the first screening question is now: “Do we permit a PBM-owned or PBM-capitalized partner in this role?” If the answer is no, the list compresses quickly.

2. Stack Breadth

The four vendors are not interchangeable.

• CarePathRx has the broadest bundled health-system stack: specialty pharmacy, home infusion, 340B TPA, telepharmacy, and GPO assets.
• CPS Solutions has the broadest pharmacy-management footprint overall, spanning inpatient, outpatient, and specialty operations through a larger hospital client base.
• Shields is the most focused specialty accelerator, which is a strength when the buyer wants specialty-pharmacy performance rather than a generalist pharmacy operator.
• Clearway Health is narrower than CarePathRx or CPS, but that narrower profile can be a feature for health systems prioritizing embedded specialty workflows over platform sprawl.

3. Contracting, 340B, and Channel Control

• Shields still has the strongest publicly articulated payer-contracting proof points, including 430+ payer contracts and network-scale leverage.
• CarePathRx and CPS Solutions offer enterprise leverage through their PBM parents, but that leverage comes with less payer neutrality.
• Clearway Health has the best governance story for systems that care about preserving a clean 340B and channel-alignment narrative, but fewer public details on payer-contract breadth.

The practical trade-off is straightforward: the PBM-aligned models can speed access and implementation, while the payer-independent model reduces structural conflict.

4. Technology and Operating Maturity

• Shields has the clearest specialty-specific technology moat through TelemetryRx.
• CarePathRx has the most diversified operating stack, but the stack is spread across more assets and services.
• CPS Solutions is operationally mature at hospital scale, though its technology story is less differentiated at the specialty-pharmacy layer.
• Clearway Health has a credible platform story through Charter, but much less public proof than Shields.

Directional Scorecard

Ratings are directional on a 1-5 scale and meant for buyer triage, not as a substitute for diligence.

Dimension	Shields	Clearway	CarePathRx	CPS Solutions	Why it matters
Scale / maturity	5	3	4	4	De-risks launch, payer access, and implementation
Payer independence	3	5	1	1	Most important 2026 strategic screen
Stack breadth	4	3	5	5	Matters when buyer wants home infusion, 340B, telepharmacy, or broader ops
Specialty-pharmacy focus	5	4	4	3	Matters when buyer wants a pure SP operator rather than a broad pharmacy manager
340B / health-system alignment	4	5	3	3	Determines economics and governance comfort
Technology differentiation	5	3	4	3	Impacts referral capture, workflow, and analytics
Payer-contract leverage	5	2	4	4	Critical for LDD access and network viability
Governance simplicity	3	5	1	1	Helps buyers avoid structural channel-conflict risk
Composite	34/40	30/40	26/40	24/40	Clear split between scale and independence archetypes

Best-For Scenarios

Shields Is Best For

• Health systems that want the most proven specialty-pharmacy accelerator
• Buyers who value payer contracts, LDD access, and a mature specialty operating system above clean independence
• Systems comfortable diligencing the Evernorth relationship rather than excluding it outright

Clearway Health Is Best For

• Health systems that want a payer-independent accelerator partner
• Safety-net, academic, and governance-sensitive buyers who care as much about structural alignment as they do about raw scale
• RFPs where PBM ownership or PBM capital is a meaningful negative screen

CarePathRx Is Best For

• Buyers wanting the broadest integrated stack across specialty pharmacy, home infusion, telepharmacy, and 340B-adjacent services
• Health systems comfortable working directly with Evernorth
• Organizations preferring one broader enterprise partner over a narrower specialty-only accelerator

CPS Solutions Is Best For

• Hospitals seeking a broad pharmacy-operations partner, not only a specialty-pharmacy accelerator
• Buyers already comfortable inside the Optum / UHG ecosystem
• Systems that value enterprise pharmacy-management depth more than a specialty-first positioning

Verdict

There is no longer a clean three-way “independent accelerator” market.

• Shields is still the best all-around accelerator if the buyer’s top priority is specialty-pharmacy scale and execution.
• Clearway Health is the most strategically important alternative because it is the only payer-independent scaled option left in the set.
• CarePathRx is the most attractive when stack breadth matters more than governance simplicity.
• CPS Solutions is strongest when the buyer wants broader pharmacy-management infrastructure, not only specialty acceleration.

The fastest way to use this page in diligence is:

1. Decide whether PBM ownership or PBM capital is acceptable.
2. Decide whether the buyer wants a specialty-first accelerator or a broader pharmacy platform.
3. Use Health System Specialty Pharmacy: Build vs. Buy vs. Partner for the larger decision framework, then return here for partner selection.

Editorial Firewall Disclosure

This comparison is written by the Rx Almanac editorial team using publicly available sources. None of the vendors named here has sponsored, reviewed, or approved this content. Feedback and correction requests are reviewed for factual accuracy; promotional edits are not accepted.